Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Update

Virax Biolabs Group Limited (NASDAQ:VRAX) was the recipient of a large decline in short interest during the month of December. As of December 31st, there was short interest totaling 95,551 shares, a decline of 36.3% from the December 15th total of 149,941 shares. Currently, 4.0% of the company’s stock are short sold. Based on an average daily volume of 547,804 shares, the days-to-cover ratio is presently 0.2 days. Based on an average daily volume of 547,804 shares, the days-to-cover ratio is presently 0.2 days. Currently, 4.0% of the company’s stock are short sold.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. HC Wainwright restated a “buy” rating and set a $1.00 price objective (down from $3.00) on shares of Virax Biolabs Group in a research note on Friday, January 9th. Weiss Ratings reissued a “sell (e+)” rating on shares of Virax Biolabs Group in a research report on Friday, January 9th. Finally, Zacks Research upgraded shares of Virax Biolabs Group to a “hold” rating in a report on Tuesday, January 13th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Virax Biolabs Group has an average rating of “Hold” and a consensus price target of $1.00.

Virax Biolabs Group Stock Down 2.5%

Virax Biolabs Group stock traded down $0.01 during midday trading on Friday, reaching $0.31. 299,633 shares of the company traded hands, compared to its average volume of 446,637. Virax Biolabs Group has a 12 month low of $0.30 and a 12 month high of $2.33. The business has a 50 day moving average of $0.42 and a two-hundred day moving average of $0.61.

Virax Biolabs Group (NASDAQ:VRAX) last announced its earnings results on Tuesday, December 2nd. The company reported ($0.27) earnings per share for the quarter. The business had revenue of $0.00 million for the quarter.

Virax Biolabs Group Company Profile

Virax Biolabs Group (NASDAQ: VRAX) is a clinical-stage biotechnology company focused on the research, development and manufacturing of next-generation vaccines targeting respiratory and other infectious diseases. Headquartered in Australia, the company leverages advanced viral vector platforms to create novel immunization solutions designed to induce both systemic and mucosal immunity. Virax Biolabs is publicly traded on the NASDAQ exchange under the symbol VRAX.

At the core of Virax Biolabs’ pipeline is a proprietary adenoviral vector platform, licensed exclusively from a leading academic institution, which serves as the backbone for intranasal and injectable vaccine candidates.